BioHarvest Sciences (BHST) to Release Earnings on Thursday

Key Points

• Q1 2026 results due before market open on Thursday, May 14 (8:00 AM ET): analysts expect EPS of ($0.13) and revenue of $8.5 million.
• Shares opened at $4.20 and trade near their 12‑month low ($4.10) vs high ($12.80); the company has a market cap of about $82.4M, a negative P/E (-6.89), 50‑/200‑day SMAs of $4.34/$5.61, strong liquidity (current ratio 3.97, quick ratio 3.38) and low leverage (debt/equity 0.10).
• Analyst coverage is mixed with a consensus "Hold" and a $10 target (Roth MKM = Buy at $10; Weiss = Sell), while several institutions initiated modest positions in Q4.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $8.50 million for the quarter. Parties can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:00 AM ET.

BioHarvest Sciences Trading Down 0.2%

Shares of NASDAQ BHST opened at $4.20 on Thursday. BioHarvest Sciences has a 12-month low of $4.10 and a 12-month high of $12.80. The company has a market cap of $82.39 million, a price-to-earnings ratio of -6.89 and a beta of 0.81. The company has a current ratio of 3.97, a quick ratio of 3.38 and a debt-to-equity ratio of 0.10. The stock's 50 day simple moving average is $4.34 and its 200 day simple moving average is $5.61.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BHST shares. Roth Mkm began coverage on shares of BioHarvest Sciences in a research note on Thursday, February 19th. They set a "buy" rating and a $10.00 target price for the company. Weiss Ratings restated a "sell (d-)" rating on shares of BioHarvest Sciences in a research report on Friday, March 27th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $10.00.

Institutional Trading of BioHarvest Sciences

A number of large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of BioHarvest Sciences in the 4th quarter worth $60,000. Geode Capital Management LLC purchased a new position in BioHarvest Sciences in the 4th quarter worth about $61,000. HRT Financial LP acquired a new stake in BioHarvest Sciences during the 4th quarter worth about $75,000. Marshall Wace LLP purchased a new stake in BioHarvest Sciences during the fourth quarter valued at about $110,000. Finally, Quadrature Capital Ltd purchased a new stake in BioHarvest Sciences during the fourth quarter valued at about $140,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company's product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.